Table 4.

SM patients: prognostic factors for PFS and OS (n = 34)

Disease featuresnUnivariate analysis
PFS, yOS, y
Median (range)PMedian (range)P
Clinical and laboratory features
 Diagnosis
  Nonadvanced SM1214 (2-32)NSNR (3-48)NS
  Advanced SM2211 (1-18)11 (1-18)
 Age at diagnosis, y
  <602314 (1-32)NSNR (1-48)NS
  ≥60115 (1-10)6 (1-12)
 Skin lesions
  No104 (1-6)NS6 (1-13)0.02
  Yes2414 (1-32)NR (3-48)
 BM MCs, %
  <1145 (1-19)NS11 (1-19)NS
  ≥11814 (1-32)NR (1-48)
 sBT, µg/L
  <2001015 (1-17)NSNR (1-17)NS
  ≥200226 (1-32)NR (1-48)
 Hemoglobin, g/L
  <10053 (1-6)NS4 (1-7).001
  ≥1002914 (1-32)NR (1-48)
 Platelets, ×109/L
  <100114 (1-15).034 (1-17).04
  ≥1002314 (1-32)NR (1-48)
 β2-microglobulin, µg/mL
  <2.57NR (2-18)NSNR (3-17).04
  ≥2.5205 (1-32)10 (1-48)
 SAP, U/L
  <1501632 (2-32).01NR (3-48).01
  ≥150144 (1-30)10 (1-39)
 Splenomegaly
  No1130 (1-30).04NR (1-39)NS
  Yes235 (1-32)11 (1-48)
 Hepatomegaly
  No1615 (1-19)NSNR (1-19)NS
  Yes185 (1-32)11 (1-48)
Number of nonsynonymous coding genetic variants
 Total somatic mutations
  0930 (2-32).02NR (3-48).005
  ≥1114 (1-15)6 (2-17)
 MC restricted
  01514 (1-32)NSNR (2-48)NS
  ≥156 (1-15)7 (6-17)
 Multilineal
  01030 (2-32).009NR (3-48).001
  ≥1103 (1-10)6 (2-10)
 Germline genetic variants
  <31714 (1-32).016NR (4-48).004
  ≥333 (1-4)4 (2-10)
 Total genetic variants
  <31130 (2-32).002NR (3-48)<.001
  ≥393 (1-6)6 (2-10)
Gene panel mutational status
 S/A/R
  WT2315 (2-32)<.001NR (3-48).002
  Mutated112 (1-4)6 (1-13)
 S/A/R/E
  WT1930 (2-32)<.001NR (3-48)<.001
  Mutated153 (1-6)6 (1-13)
  • NR, not reached; NS, not statistically significant (P > .05); SAP, serum alkaline phosphatase; WT, wild-type.